• Publications
  • Influence
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
BACKGROUND BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramerExpand
  • 907
  • 69
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectivelyExpand
  • 1,158
  • 47
  • PDF
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
Degeneration of chronically demyelinated axons is a major cause of irreversible neurological disability in multiple sclerosis (MS) patients. Development of neuroprotective therapies will requireExpand
  • 682
  • 42
  • PDF
Defining the clinical course of multiple sclerosis
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatmentExpand
  • 750
  • 33
  • PDF
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of rituximab 6Expand
  • 375
  • 16
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
BACKGROUND No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, aExpand
  • 202
  • 12
  • PDF
Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the human central nervous system. Although the clinical impact of gray matter pathology in MS brains is unknown, 30 to 40% of MSExpand
  • 202
  • 11
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Generation and differentiation of new oligodendrocytes in demyelinated white matter is the best described repair process in the adult human brain. However, remyelinating capacity falters with age inExpand
  • 131
  • 11
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile for patients with relapsing–remitting multiple sclerosis (RRMS) in phase 3Expand
  • 82
  • 10
  • PDF
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
BACKGROUND Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder. Recently, much has become known about its immunopathogenesis. However, optimal treatments,Expand
  • 284
  • 8